Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $4.00 Consensus Price Target from Analysts

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) has been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $4.00.

Several brokerages recently weighed in on TNYA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tenaya Therapeutics in a report on Wednesday, January 21st. William Blair reissued an “outperform” rating on shares of Tenaya Therapeutics in a research report on Thursday. Chardan Capital restated a “buy” rating and issued a $8.00 price objective on shares of Tenaya Therapeutics in a report on Thursday, March 12th. Canaccord Genuity Group decreased their price objective on shares of Tenaya Therapeutics from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Finally, HC Wainwright lowered their target price on shares of Tenaya Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, December 12th.

Insider Transactions at Tenaya Therapeutics

In other news, major shareholder Group Gp Lp Column III sold 3,511,826 shares of the company’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $0.56, for a total transaction of $1,966,622.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders sold 8,594,047 shares of company stock worth $5,430,207. 48.65% of the stock is owned by insiders.

Institutional Investors Weigh In On Tenaya Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Savant Capital LLC purchased a new position in Tenaya Therapeutics in the second quarter valued at approximately $52,000. Corient Private Wealth LLC purchased a new stake in shares of Tenaya Therapeutics during the 4th quarter worth approximately $72,000. Cerity Partners LLC lifted its position in shares of Tenaya Therapeutics by 403.5% during the 2nd quarter. Cerity Partners LLC now owns 110,336 shares of the company’s stock worth $67,000 after buying an additional 88,424 shares during the last quarter. Comerica Bank acquired a new position in shares of Tenaya Therapeutics in the 1st quarter valued at $50,000. Finally, Scientech Research LLC acquired a new position in shares of Tenaya Therapeutics in the 3rd quarter valued at $27,000. Institutional investors and hedge funds own 90.54% of the company’s stock.

Tenaya Therapeutics Stock Up 0.6%

NASDAQ:TNYA opened at $0.86 on Friday. Tenaya Therapeutics has a 52 week low of $0.36 and a 52 week high of $2.35. The company has a fifty day simple moving average of $0.74 and a two-hundred day simple moving average of $1.12. The company has a market cap of $140.34 million, a price-to-earnings ratio of -1.38 and a beta of 3.22.

Tenaya Therapeutics (NASDAQ:TNYA) last released its earnings results on Wednesday, March 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.12). On average, analysts expect that Tenaya Therapeutics will post -1.35 EPS for the current year.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.